Quest Diagnostics Incorporated Agreed to Pay $48,000 for Allegedly Violating the Civil Monetary Penalties Law by Submitting Claims for Non-Covered Services
On December 7, 2021, Quest Diagnostics Incorporated and its subsidiaries (Quest), headquartered in New Jersey, entered into a $48,953.22 settlement agreement with OIG. The settlement agreement resolves allegations that Quest submitted claims to Medicare for specimen validity testing (SVT) in conjunction with claims for urine drug testing when SVT was a non-covered service. OIG's Office of Audit Services and Office of Counsel to the Inspector General, represented by Senior Counsels Gregory Becker and Andrea Treese Berlin with the assistance of Paralegal Specialist Jennifer Hilton, collaborated to achieve this resolution.
- Date:December 7, 2021
- CMP and Affirmative Exclusions